Publications by authors named "B Adamo"
Background: Predictors of response to neoadjuvant chemotherapy (NACT) and endocrine therapy (NET) in hormone receptor-positive (HoR+)/human epidermal growth factor receptor 2 (HER2)-negative breast cancer (BC) are required. Also, pathological and molecular changes induced by both strategies and their impact on patients' outcomes have not been reported so far.
Patients And Methods: In a cohort of 186 patients with early-stage HoR+/HER2-negative BC treated with NACT or NET, we assessed the association of baseline main clinicopathological features and PAM50 gene expression (GE), intrinsic subtypes (IS) and risk-of-relapse (ROR-P) score with pathological outcomes according to treatment strategy.
The incidence of breast cancer in ≤ 40 yr-old women (YWBC) has been steadily increasing in recent decades. Although this group of patients represents less than 10 % of all newly diagnosed BC cases it encompasses a significant burden of disease. Usually underrepresented in clinical trials, YWBCs are also characterized by late diagnoses and poorly differentiated, aggressive-subtype disease, partly explaining its poor prognosis along with a high recurrence risk, and high mortality rates.
View Article and Find Full Text PDFArticle Synopsis
- * Researchers tested these drugs on various breast cancer cell lines and patient tumor samples, evaluating their impact on cell proliferation, key protein levels, and gene expression over different time frames and doses.
- * Findings indicate that both drugs effectively reduce cancer cell growth and alter gene signatures, but their effects on the HER2-enriched signature may vary according to dosage and additional treatments like fulvestrant, highlighting the need for continued research.
Background: The characterization and comparison of gene expression and intrinsic subtype (IS) changes induced by neoadjuvant chemotherapy (NACT) and endocrine therapy in hormone receptor-positive (HR+)/human epidermal growth factor receptor 2 (HER2)-low versus HR+/HER2-0 breast cancer (BC) has not been conducted so far. Most evidence on the association of HER2 status with pathologic responses and prognosis in HR+/HER2-negative BC is controversial and restricted to NACT-treated disease. Similarly, a temporal heterogeneity in HER2 status has been described only with NACT.
View Article and Find Full Text PDFArticle Synopsis
- Early-stage triple-negative breast cancer (TNBC) has variability in its clinical and biological characteristics, with immune infiltration impacting prognosis, and there’s a need for better genomic tools for treatment decisions.
- This study analyzed genomic and clinical data across seven patient cohorts to evaluate the role of a B-cell/immunoglobulin signature (IGG) in predicting event-free survival (EFS) and overall survival (OS) in TNBC patients.
- Results indicated that IGG is associated with improved EFS and OS, and its integration with tumor staging can help identify patients who may benefit from tailored treatments.